- Amgen (NasdaqGS:AMGN) reported new Phase 3 VESALIUS-CV trial results for Repatha (evolocumab) showing a reduction in risk of death for high-risk adults without prior heart attack or stroke, presented at the European Society of Cardiology Congress 2026.
- The findings extend evidence for Repatha to a broader high-risk population beyond patients with established cardiovascular events.
- Amgen highlighted that the data may inform future treatment guidelines and prescribing decisions in cardiovascular risk management.
Repatha is one part of a wider shift in how healthcare uses data and advanced tools to manage risk. Investors tracking this theme may want to look at a broader set of related stocks via 39 healthcare AI stocks.
Amgen is a US based biotech company with a market cap of about $232.4 billion that focuses on discovering and developing human therapeutics. Repatha sits within its cardiovascular portfolio, which is one part of a wider pipeline that targets serious chronic diseases.
We've flagged 1 risk for Amgen. See which could impact your investment.
Repatha results support Amgen’s push into larger high risk populations
For investors, this Repatha update fits neatly into Amgen’s Narrative around expanding treatments for chronic diseases and reaching under treated populations. Evidence that Repatha reduces the risk of death in high risk adults without a prior heart attack or stroke broadens its relevance beyond secondary prevention and supports the view that cardiovascular programs can contribute to diversified, higher margin biologics revenue alongside biosimilars. It also leans into the Narrative catalyst that highlights Repatha and other late stage cardiovascular drugs as key to sustaining revenue growth while pricing pressure and biosimilar competition weigh on older franchises.
If we take a look at the community Narrative for Amgen, we can see how this news fits into the bigger investment story.
From here, the key marker to watch is how quickly guideline bodies and payers respond to the VESALIUS CV data, including any formal label or reimbursement changes referenced around the 2026 European Society of Cardiology presentation. Subsequent prescription trends in high risk primary prevention patients, relative to current use in established cardiovascular disease, will help show whether Repatha is simply holding its ground or starting to address a wider share of the eligible population in line with Amgen’s chronic disease growth thesis.
For the full picture including more risks and rewards, check out the complete Amgen analysis.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com